EGFR and neoplasm: However, since it is now recognised that the most robust tumour responses noted with EGFR inhibitors occur in patients with activating EGFR mutations (Lynch et al, 2004), it is not surprising that dose escalation of erlotinib to the maximal dose associated with a TR did not result in an increased response rate in this unselected patient population.